List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1922105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
2	Small extracellular vesicle-mediated <i>ITGB6</i> siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells. Cancer Biology and Therapy, 2022, 23, 173-185.	1.5	12
3	Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression. PLoS ONE, 2021, 16, e0244985.	1.1	16
4	A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression. Science Advances, 2021, 7, .	4.7	19
5	IFIT3 (Interferon Induced Protein with Tetratricopeptide Repeats 3) Modulates STAT1 Expression in small Extracellular Vesicles. Biochemical Journal, 2021, 478, 3905-3921.	1.7	3
6	Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment. Developmental Cell, 2020, 55, 163-177.e6.	3.1	26
7	The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Science Signaling, 2020, 13, .	1.6	51
8	Hitting the Bullseye: Are extracellular vesicles on target?. Journal of Extracellular Vesicles, 2020, 10, e12032.	5.5	11
9	Small extracellular vesicles modulated by αVβ3Âintegrin induce neuroendocrine differentiation in recipient cancer cells. Journal of Extracellular Vesicles, 2020, 9, 1761072.	5.5	32
10	The αvβ6Âintegrin in cancer cellâ€derived small extracellular vesicles enhances angiogenesis. Journal of Extracellular Vesicles, 2020, 9, 1763594.	5.5	41
11	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
12	Methods for extracellular vesicle isolation from cancer cells. , 2020, 3, 371-384.		3
13	Prostate cancer sheds the αvβ3 integrin in vivo through exosomes. Matrix Biology, 2019, 77, 41-57.	1.5	73
14	MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer. Cancer Research, 2019, 79, 6215-6226.	0.4	34
15	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. Molecular and Cellular Biology, 2019, 39, .	1.1	31
16	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. Journal of Biological Chemistry, 2019, 294, 10407-10414.	1.6	25
17	Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth. IScience, 2019, 14, 199-209.	1.9	29
18	Activated Extracellular Vesicles as New Therapeutic Targets?. Trends in Cell Biology, 2019, 29, 276-278.	3.6	2

#	Article	IF	CITATIONS
19	αvβ3 Integrin Mediates Radioresistance of Prostate Cancer Cells through Regulation of Survivin. Molecular Cancer Research, 2019, 17, 398-408.	1.5	31
20	Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model. Statistics in Biopharmaceutical Research, 2018, 10, 112-122.	0.6	86
21	Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biology, 2018, 70, 20-35.	1.5	54
22	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	5.5	6,961
23	Unique pattern of neutrophil migration and function during tumor progression. Nature Immunology, 2018, 19, 1236-1247.	7.0	140
24	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Research, 2018, 78, 4215-4228.	0.4	47
25	c‧rc, Insulinâ€Like Growth Factor I Receptor, Gâ€Proteinâ€Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes. Journal of Cellular Biochemistry, 2017, 118, 66-73.	1.2	74
26	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017, 32, 654-668.e5.	7.7	457
27	Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. Journal of Clinical Investigation, 2017, 127, 3755-3769.	3.9	37
28	The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biology, 2016, 14, e1002507.	2.6	118
29	A neuronal network of mitochondrial dynamics regulates metastasis. Nature Communications, 2016, 7, 13730.	5.8	112
30	Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell, 2016, 30, 257-272.	7.7	158
31	αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Research, 2016, 76, 5163-5174.	0.4	32
32	v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Research, 2016, 76, 6723-6734.	0.4	22
33	Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Molecular Cancer Research, 2016, 14, 1136-1146.	1.5	115
34	Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. Journal of Biological Chemistry, 2016, 291, 25247-25254.	1.6	29
35	CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 2016, 44, 303-315.	6.6	299
36	β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. Oncotarget, 2016, 7, 52618-52630.	0.8	6

#	Article	IF	CITATIONS
37	A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget, 2016, 7, 70462-70474.	0.8	21
38	Exosome-mediated transfer from the tumor microenvironment increases TGFÎ ² signaling in squamous cell carcinoma. American Journal of Translational Research (discontinued), 2016, 8, 2432-7.	0.0	49
39	Deletion of Cyclophilin D Impairs β-Oxidation and Promotes Glucose Metabolism. Scientific Reports, 2015, 5, 15981.	1.6	34
40	Expression of the ILâ€11 Gene in Metastatic Cells Is Supported by Runx2â€5mad and Runx2â€cJun Complexes Induced by TGFβ1. Journal of Cellular Biochemistry, 2015, 116, 2098-2108.	1.2	21
41	The αvβ6 Integrin Is Transferred Intercellularly via Exosomes. Journal of Biological Chemistry, 2015, 290, 4545-4551.	1.6	140
42	αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression. Biochemical Journal, 2015, 466, 525-536.	1.7	27
43	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	3.3	174
44	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	91
45	Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Science Signaling, 2015, 8, ra80.	1.6	84
46	Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. American Journal of Pathology, 2015, 185, 2505-2522.	1.9	54
47	Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. PLoS ONE, 2015, 10, e0130060.	1.1	23
48	Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget, 2015, 6, 14318-14328.	0.8	58
49	Integrin αvβ6 Promotes an Osteolytic Program in Cancer Cells by Upregulating MMP2. Cancer Research, 2014, 74, 1598-1608.	0.4	61
50	Deletion of the Mitochondrial Chaperone TRAP-1ÂUncovers Global Reprogramming of Metabolic Networks. Cell Reports, 2014, 8, 671-677.	2.9	64
51	Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 2013, 4, 2139.	5.8	135
52	β ₁ integrins mediate resistance to ionizing radiation in vivo by inhibiting câ€Jun amino terminal kinase 1. Journal of Cellular Physiology, 2013, 228, 1601-1609.	2.0	44
53	Trop-2 Promotes Prostate Cancer Metastasis By Modulating β1 Integrin Functions. Cancer Research, 2013, 73, 3155-3167.	0.4	103
54	Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. Journal of Clinical Investigation, 2013, 123, 2907-2920.	3.9	165

#	Article	IF	CITATIONS
55	IGF-IR Promotes Prostate Cancer Growth by Stabilizing α5β1 Integrin Protein Levels. PLoS ONE, 2013, 8, e76513.	1.1	32
56	Control of Tumor Bioenergetics and Survival Stress Signaling by Mitochondrial HSP90s. Cancer Cell, 2012, 22, 331-344.	7.7	103
57	PSA regulates androgen receptor expression in prostate cancer cells. Prostate, 2012, 72, 769-776.	1.2	30
58	Tropâ€2 inhibits prostate cancer cell adhesion to fibronectin through the β ₁ integrinâ€RACK1 axis. Journal of Cellular Physiology, 2012, 227, 3670-3677.	2.0	58
59	TRAP-1, the mitochondrial Hsp90. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 767-773.	1.9	156
60	Insulinâ€ l ike growth factor 1 stimulation of androgen receptor activity requires β _{1A} integrins. Journal of Cellular Physiology, 2012, 227, 751-758.	2.0	35
61	α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. American Journal of Translational Research (discontinued), 2012, 4, 165-74.	0.0	13
62	The Search for a Better Prostate Cancer Biomarker. Journal of Urology, 2011, 186, 1758-1759.	0.2	1
63	Molecular Targets for Radiation Oncology in Prostate Cancer. Frontiers in Oncology, 2011, 1, 17.	1.3	12
64	Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. British Journal of Cancer, 2011, 104, 629-634.	2.9	58
65	IAP Regulation of Metastasis. Cancer Cell, 2010, 17, 53-64.	7.7	258
66	The cancerâ€related Runx2 protein enhances cell growth and responses to androgen and TGFβ in prostate cancer cells. Journal of Cellular Biochemistry, 2010, 109, 828-837.	1.2	43
67	β1 integrins mediate cell proliferation in threeâ€dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. Journal of Cellular Physiology, 2010, 224, 210-217.	2.0	30
68	Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene, 2010, 29, 811-821.	2.6	246
69	Protein Kinase D1 Inhibits Cell Proliferation through Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Secretion in Prostate Cancer. Cancer Research, 2010, 70, 2095-2104.	0.4	48
70	Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer. Clinical Cancer Research, 2010, 16, 4779-4788.	3.2	85
71	Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. American Journal of Pathology, 2010, 176, 393-401.	1.9	113
72	CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. American Journal of Translational Research (discontinued), 2010, 2, 135-44.	0.0	41

#	Article	IF	CITATIONS
73	Endogenous Tumor Suppression Mediated by <i>PTEN</i> Involves <i>Survivin</i> Gene Silencing. Cancer Research, 2009, 69, 4954-4958.	0.4	61
74	β1 Integrin Cytoplasmic Variants Differentially Regulate Expression of the Antiangiogenic Extracellular Matrix Protein Thrombospondin 1. Cancer Research, 2009, 69, 5374-5382.	0.4	13
75	Prostate cancer regulatory networks. Journal of Cellular Biochemistry, 2009, 107, 845-852.	1.2	32
76	Integrin signaling aberrations in prostate cancer. American Journal of Translational Research (discontinued), 2009, 1, 211-20.	0.0	28
77	Bicalutamide inhibits androgenâ€mediated adhesion of prostate cancer cells exposed to ionizing radiation. Prostate, 2008, 68, 1734-1742.	1.2	8
78	Integrins in prostate cancer progression. Endocrine-Related Cancer, 2008, 15, 657-664.	1.6	154
79	Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Review of Anticancer Therapy, 2008, 8, 967-974.	1.1	21
80	"D" approach to prevent metastasis. Cancer Biology and Therapy, 2007, 6, 110-111.	1.5	0
81	The integrin—growth factor receptor duet. Journal of Cellular Physiology, 2007, 213, 649-653.	2.0	146
82	Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene, 2007, 26, 2678-2684.	2.6	162
83	Androgen action series. Journal of Cellular Biochemistry, 2006, 99, 331-332.	1.2	0
84	β1 Integrins Modulate Cell Adhesion by Regulating Insulin-Like Growth Factor-II Levels in the Microenvironment. Cancer Research, 2006, 66, 331-342.	0.4	25
85	High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and β1 integrin expression. Prostate, 2005, 64, 83-91.	1.2	21
86	The Runx2 Osteogenic Transcription Factor Regulates Matrix Metalloproteinase 9 in Bone Metastatic Cancer Cells and Controls Cell Invasion. Molecular and Cellular Biology, 2005, 25, 8581-8591.	1.1	280
87	β1A Integrin Expression Is Required for Type 1 Insulin-Like Growth Factor Receptor Mitogenic and Transforming Activities and Localization to Focal Contacts. Cancer Research, 2005, 65, 6692-6700.	0.4	69
88	Correction: Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins. Journal of Cell Biology, 2004, 167, 565-565.	2.3	0
89	Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins. Journal of Cell Biology, 2004, 166, 407-418.	2.3	77
90	Regulation of β1C and β1A Integrin Expression in Prostate Carcinoma Cells. Journal of Biological Chemistry, 2004, 279, 1692-1702.	1.6	32

#	Article	IF	CITATIONS
91	Advances in prostate cancer research. Journal of Cellular Biochemistry, 2004, 91, 1-2.	1.2	0
92	Advances in prostate cancer research: part III. Journal of Cellular Biochemistry, 2004, 91, 647-648.	1.2	0
93	Integrin Signaling in Cancer. , 2004, 119, 15-31.		30
94	αvβ3 integrin expression up-regulates cdc2, which modulates cell migration. Journal of Cell Biology, 2003, 161, 817-826.	2.3	126
95	Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway. Journal of Biological Chemistry, 2003, 278, 50402-50411.	1.6	133
96	Integrins and prostate cancer metastases. , 2002, , 185-195.		0
97	Regulation of MCP-3 and BRCA2 mRNA Expression Levels by β1 Integrins. Experimental and Molecular Pathology, 2001, 70, 239-247.	0.9	4
98	Epitope-Specific Antibodies to the β1C Integrin Cytoplasmic Domain Variant. Experimental and Molecular Pathology, 2001, 70, 275-280.	0.9	2
99	Integrins and prostate cancer metastases. Cancer and Metastasis Reviews, 2001, 20, 321-331.	2.7	102
100	Vascular Endothelial Growth Factor–Stimulated Actin Reorganization and Migration of Endothelial Cells Is Regulated via the Serine/Threonine Kinase Akt. Circulation Research, 2000, 86, 892-896.	2.0	386
101	Differential Role of β1Cand β1AIntegrin Cytoplasmic Variants in Modulating Focal Adhesion Kinase, Protein Kinase B/AKT, and Ras/Mitogen-activated Protein Kinase Pathways. Molecular Biology of the Cell, 2000, 11, 2235-2249.	0.9	48
102	Substrate Specificity of αvβ3Integrin-mediated Cell Migration and Phosphatidylinositol 3-Kinase/AKT Pathway Activation. Journal of Biological Chemistry, 2000, 275, 24565-24574.	1.6	136
103	Down-Regulation of Î ² 1C Integrin in Breast Carcinomas Correlates with High Proliferative Fraction, High Histological Grade, and Larger Size. American Journal of Pathology, 2000, 156, 169-174.	1.9	31
104	Regulation of mRNA and Protein Levels of β1 Integrin Variants in Human Prostate Carcinoma. American Journal of Pathology, 2000, 157, 1727-1734.	1.9	47
105	Expression of Heterologous Integrin Genes. , 1999, 129, 125-134.		0
106	p27kip1 acts as a downstream effector of and is coexpressed with the β1C integrin in prostatic adenocarcinoma. Journal of Clinical Investigation, 1999, 103, 321-329.	3.9	47
107	Integrin laminin receptor profile of pulmonary squamous cell and adenocarcinomas. Human Pathology, 1998, 29, 1208-1215.	1.1	30
108	β1C Integrin in Epithelial Cells Correlates with a Nonproliferative Phenotype. American Journal of Pathology, 1998, 153, 1079-1087.	1.9	45

#	Article	IF	CITATIONS
109	Molecular Identification of a Novel Fibrinogen Binding Site on the First Domain of ICAM-1 Regulating Leukocyte-Endothelium Bridging. Journal of Biological Chemistry, 1997, 272, 435-441.	1.6	110
110	Alternatively spliced variants: A new view of the integrin cytoplasmic domain. Matrix Biology, 1997, 16, 185-193.	1.5	74
111	Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1505-1509.	3.3	180
112	Structural Recognition of a Novel Fibrinogen γ Chain Sequence (117 – 133) by Intercellular Adhesion Molecule-1 Mediates Leukocyte-Endothelium Interaction. Journal of Biological Chemistry, 1995, 270, 696-699.	1.6	100
113	The Novel Structural Motif Gln795–Gln802 in the Integrin β1C Cytoplasmic Domain Regulates Cell Proliferation. Journal of Biological Chemistry, 1995, 270, 24666-24669.	1.6	51
114	Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell, 1993, 73, 1423-1434.	13.5	334